Healthtech M&A | Advice & Reports

Healthtech & subsectors

Healthcare Vertical Software
Health IT Services & BPO
Online Health Services
EHR & Information Management
Medical Hardware

Hampleton‘s Healthtech practice is headed by Jonathan Simnett and Dr. Jan Eiben. Our team’s relationships with investors, acquirers and entrepreneurs spans the globe from the Americas, through EMEA and into the Asia-Pacific region. It includes the most innovative vendors of relevant technologies such as AI, AR/VR, data analytics, computer vision, connected care, diagnostics, HRM, imaging systems, sensor technology, software, and much more.

The Hampleton team members have many years of experience advising companies in health services, medical technology, and pharmaceutical industries. With international experience in healthcare, life science, insurance and government, they have led transactions in archiving, electronic data interchange, governance, risk management, compliance, records and back office management systems.

We have worked for and closed transactions with companies such as Blue Shield, Certara, FBGS, Greenlight, Neoteryx and SAGlobal.

Hampleton advised the shareholders of Berlin-based BaseCase, creators of a data visualisation SaaS platform, in the sale of their company to the New Jersey-headquartered global leader in regulatory science, Certara, an EQT portfolio company. Bringing together a niche technology vendor and the right buyer with a full suite of synergistic products and services requires in-depth industry knowledge and experience. The BaseCase / Certara transaction highlights Hampleton’s understanding, creativity and capabilities in finding the best matches in healthtech, enterprise software and SaaS.

Featured transaction

The sale of BaseCase to Certara

Hampleton Partners advised on the sale of Germany’s BaseCase data visualisation software as a service (SaaS) company to US-based Certara, the global leader in model-informed drug development and regulatory science. BaseCase‘s interactive platform improves how life science companies communicate and present that value, whether to C-suite executives, physicians or healthcare providers.

By integrating content creation with sales enablement, it allows users to quickly create and personalize a visual value proposition around a drug or device’s ROI and business case.

Director

Jonathan Simnett

Jonathan has been involved in the enterprise technology business for over three decades, managing and turning around existing business and helping management and their investors in fast-growth technology segments to grow, manage change, enter markets, transfer technologies, acquire, merge and sell. He’s worked with large and public infrastructure and system integration companies including: AT&T, Avaya, BroadSoft, BT, C&W, Cisco, HP, Global Switch, GMC, Huawei, Informix, Infosys, Intel, Myriad Group, Novell, IBM, IGT, Nortel, OpenReach, Pace, TCS, and Sybase.

Contact Jonathan

Managing Director

Dr. Jan Eiben

Jan is based in Germany. His career over the last 15 years includes extensive experience in international M&A projects of various industries on the buy and sell sides. In addition, he also worked as a management consultant advising corporations, family businesses and start-ups in strategy and organizational development projects as well as succession management.

Jan holds a PhD and MSc in Business Administration and Economics from WHU - Otto Beisheim School of Management with exchange semesters in the USA and Canada. He is fluent in German (native), English and French.

Contact Jan

Download now

Healthtech Report 1H2022

There is growing appetite to apply Artificial Intelligence (AI) and digital solutions to solve many of medicine's pressing problems. This was been exacerbated by the coronavirus pandemic in 2020.

Healthtech-1H2022-report-cover-thumbnail-list-page-FINAL

Events

Mar

2023

Cologne, Germany

Erfolgreiche Exit-Planung für Tech-Unternehmen in 2023 - Tech M&A Executive Roundtable in Köln

News

IT & Business Tech: The 3 Spaces Acquirers Care About

Hampleton Partners’ newest IT & Business Tech industry report is now out, and one of the key takeaways comes right at the start. Namely: “Worldwide IT spending is projected to total $4.6 trillion in 2023, an increase of 5.1% from 2022.”

Read on

“We selected Hampleton because of their strong track record, experience and breadth of relationships in information management and enterprise software – which proved highly valuable to our transaction process.”

Steffi Körner, CEO of FAST LTA

“Hampleton led a structured process and was able to execute a great deal with the optimal partner for us."

Pascal Ruß, CEO of Simi Reality Motion Systems

"Hampleton’s level of experience and, above all, profound understanding of the automotive market, led us to the best possible transaction."

Carel van Helsdingen, Founder & CEO of 2getthere

"Hampleton were creative - they didn't think in one direction, they thought about the whole ecosystem in order to find the right partner for us."

Ken Belotsky, Chairman at Bright Box

"It‘s not only about selling your company but thinking about the next strategic step. In this regard we had very strong support from Hampleton."

Gregor Walter, CEO at pixi*

“It was a pleasure working with Hampleton Partners. From beginning to end, they managed every aspect of the process and brought together the optimal transaction for all our stakeholders while remaining an independent company.”

Ilkka Starck, CEO at Profit Software

“It was incredible working with the Hampleton team while finding a 'new home' for my life’s work. After over four decades building Tonbeller AG, I was able to secure the best partner amongst many interested parties. Hampleton managed every detail of the project and led the auction resulting in signing and closing within seven months. We were very happy with the results which were beyond our highest expectations.”

Rutger Hetzler, CEO at Tonbeller AG

"Hampleton have their heart in it. They know and enjoy what they are doing, and we trusted them wholeheartedly."

Gijs Hubben, CEO at BaseCase

“The Hampleton team never let up and helped us secure the growth financing we were looking for, with an investor from the industry bringing not just money but also know how and market relevant connections. Hampleton thinks strategically, not just financially.”

Dr. Eric Lindner, CEO at FBGS

“I was very impressed with Hampleton’s understanding of the high tech industrial products FBGS produces and their global network which enabled us to find our Munich based co-investor in California.”

Stephan Beier, Senior Investment Manager at bm|t beteiligungsmanagement thüringen

“With X2 Equity we won a new investor that not only supports us financially, but also brings vast experience in entrepreneurship in scaling technology businesses, further providing us with complementary operational resources and support.”